Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Dual-modal magnetic resonance/fluorescent zinc probes for pancreatic β-cell mass imaging.

Stasiuk GJ, Minuzzi F, Sae-Heng M, Rivas C, Juretschke HP, Piemonti L, Allegrini PR, Laurent D, Duckworth AR, Beeby A, Rutter GA, Long NJ.

Chemistry. 2015 Mar 23;21(13):5023-33. doi: 10.1002/chem.201406008. Epub 2015 Mar 3.

2.

Tumour T1 changes in vivo are highly predictive of response to chemotherapy and reflect the number of viable tumour cells--a preclinical MR study in mice.

Weidensteiner C, Allegrini PR, Sticker-Jantscheff M, Romanet V, Ferretti S, McSheehy PM.

BMC Cancer. 2014 Feb 14;14:88. doi: 10.1186/1471-2407-14-88.

3.

Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.

Oehler C, Frei K, Rushing EJ, McSheehy PM, Weber D, Allegrini PR, Weniger D, Lütolf UM, Knuth A, Yonekawa Y, Barath K, Broggini-Tenzer A, Pruschy M, Hofer S.

Oncology. 2012;83(1):1-9. doi: 10.1159/000339152. Epub 2012 Jun 8.

4.

Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET.

Honer M, Ebenhan T, Allegrini PR, Ametamey SM, Becquet M, Cannet C, Lane HA, O'Reilly TM, Schubiger PA, Sticker-Jantscheff M, Stumm M, McSheehy PM.

Transl Oncol. 2010 Aug 1;3(4):264-75.

5.

Quantified tumor t1 is a generic early-response imaging biomarker for chemotherapy reflecting cell viability.

McSheehy PM, Weidensteiner C, Cannet C, Ferretti S, Laurent D, Ruetz S, Stumm M, Allegrini PR.

Clin Cancer Res. 2010 Jan 1;16(1):212-25. doi: 10.1158/1078-0432.CCR-09-0686. Epub 2009 Dec 15.

6.

Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents.

O'Reilly T, McSheehy PM, Kawai R, Kretz O, McMahon L, Brueggen J, Bruelisauer A, Gschwind HP, Allegrini PR, Lane HA.

Cancer Chemother Pharmacol. 2010 Mar;65(4):625-39. doi: 10.1007/s00280-009-1068-8. Epub 2009 Sep 27.

PMID:
19784839
7.

Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics.

Ferretti S, Allegrini PR, Becquet MM, McSheehy PM.

Neoplasia. 2009 Sep;11(9):874-81.

8.

Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.

Nick H, Allegrini PR, Fozard L, Junker U, Rojkjaer L, Salie R, Niederkofler V, O'Reilly T.

Exp Biol Med (Maywood). 2009 May;234(5):492-503. doi: 10.3181/0811-RM-337. Epub 2009 Feb 20.

PMID:
19234060
9.

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.

Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.

Clin Cancer Res. 2009 Mar 1;15(5):1612-22. doi: 10.1158/1078-0432.CCR-08-2057. Epub 2009 Feb 17.

10.

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.

Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, García-Echeverría C, Maira SM.

Cancer Res. 2008 Aug 15;68(16):6598-607. doi: 10.1158/0008-5472.CAN-08-1044.

11.

Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.

O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM.

Cancer Chemother Pharmacol. 2008 Nov;62(6):1045-54. doi: 10.1007/s00280-008-0695-9. Epub 2008 Feb 27.

PMID:
18301895
12.

First in vivo MRI assessment of a self-assembled metallostar compound endowed with a remarkable high field relaxivity.

Livramento JB, Weidensteiner C, Prata MI, Allegrini PR, Geraldes CF, Helm L, Kneuer R, Merbach AE, Santos AC, Schmidt P, Tóth E.

Contrast Media Mol Imaging. 2006 Jan-Feb;1(1):30-9.

PMID:
17193598
13.

Quantitative dynamic contrast-enhanced MRI in tumor-bearing rats and mice with inversion recovery TrueFISP and two contrast agents at 4.7 T.

Weidensteiner C, Rausch M, McSheehy PM, Allegrini PR.

J Magn Reson Imaging. 2006 Sep;24(3):646-56.

PMID:
16878308
14.

Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure.

Ferretti S, Allegrini PR, O'Reilly T, Schnell C, Stumm M, Wartmann M, Wood J, McSheehy PM.

Clin Cancer Res. 2005 Nov 1;11(21):7773-84.

15.

PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.

Rudin M, McSheehy PM, Allegrini PR, Rausch M, Baumann D, Becquet M, Brecht K, Brueggen J, Ferretti S, Schaeffer F, Schnell C, Wood J.

NMR Biomed. 2005 Aug;18(5):308-21.

PMID:
15918178
16.

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity.

Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, Thomas G.

Nature. 2004 Sep 9;431(7005):200-5. Epub 2004 Aug 11. Erratum in: Nature. 2004 Sep 23;431(7007):485.

PMID:
15306821
17.

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.

Cancer Res. 2004 Jul 15;64(14):4931-41.

18.

Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke.

Linton SD, Aja T, Allegrini PR, Deckwerth TL, Diaz JL, Hengerer B, Herrmann J, Jahangiri KG, Kallen J, Karanewsky DS, Meduna SP, Nalley K, Robinson ED, Roggo S, Rovelli G, Sauter A, Sayers RO, Schmitz A, Smidt R, Ternansky RJ, Tomaselli KJ, Ullman BR, Wiessner C, Wu JC.

Bioorg Med Chem Lett. 2004 May 17;14(10):2685-91.

PMID:
15109679
19.
20.

Characterization of CNS disorders and evaluation of therapy using structural and functional MRI.

Rudin M, Mueggler T, Allegrini PR, Baumann D, Rausch M.

Anal Bioanal Chem. 2003 Nov;377(6):973-81. Epub 2003 Aug 26. Review.

PMID:
12942228
21.

Functional-morphologic MR imaging with ultrasmall superparamagnetic particles of iron oxide in acute and chronic soft-tissue infection: study in rats.

Kaim AH, Jundt G, Wischer T, O'Reilly T, Frohlich J, von Schulthess GK, Allegrini PR.

Radiology. 2003 Apr;227(1):169-74. Epub 2003 Feb 28.

PMID:
12615996
22.

Anti-Nogo-A antibody infusion 24 hours after experimental stroke improved behavioral outcome and corticospinal plasticity in normotensive and spontaneously hypertensive rats.

Wiessner C, Bareyre FM, Allegrini PR, Mir AK, Frentzel S, Zurini M, Schnell L, Oertle T, Schwab ME.

J Cereb Blood Flow Metab. 2003 Feb;23(2):154-65.

PMID:
12571447
23.

MRI predicts area of increased plasminogen activation in permanent focal cerebral ischemia.

Pfefferkorn T, Wiessner C, Allegrini PR, Kloss CU, Hamann GF.

Neurol Res. 2002 Dec;24(8):822-4.

PMID:
12500707
24.

MR imaging with ultrasmall superparamagnetic iron oxide particles in experimental soft-tissue infections in rats.

Kaim AH, Wischer T, O'Reilly T, Jundt G, Fröhlich J, von Schulthess GK, Allegrini PR.

Radiology. 2002 Dec;225(3):808-14.

PMID:
12461265
25.
26.

PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.

Drevs J, Müller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H, Konerding MA, Allegrini PR, Wood J, Hennig J, Unger C, Marmé D.

Cancer Res. 2002 Jul 15;62(14):4015-22.

27.

Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy.

Winkler DT, Biedermann L, Tolnay M, Allegrini PR, Staufenbiel M, Wiessner C, Jucker M.

Ann Neurol. 2002 Jun;51(6):790-3.

PMID:
12112090
28.

Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model.

Hughes PM, Allegrini PR, Rudin M, Perry VH, Mir AK, Wiessner C.

J Cereb Blood Flow Metab. 2002 Mar;22(3):308-17.

PMID:
11891436
29.

Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin.

Wiessner C, Allegrini PR, Ekatodramis D, Jewell UR, Stallmach T, Gassmann M.

J Cereb Blood Flow Metab. 2001 Jul;21(7):857-64.

PMID:
11435798
30.

From anatomy to the target: contributions of magnetic resonance imaging to preclinical pharmaceutical research.

Beckmann N, Mueggler T, Allegrini PR, Laurent D, Rudin M.

Anat Rec. 2001 Apr;265(2):85-100. Review.

31.

In-vivo cardiac studies in animals using magnetic resonance techniques: experimental aspects and MR readouts.

Rudin M, Allegrini PR, Beckmann N, Ekatodramis D, Laurent D.

MAGMA. 2000 Nov;11(1-2):33-5. Review. No abstract available.

PMID:
11186979
32.

Combined blockade of endothelin-1 and thromboxane A(2) receptors against postischaemic contractile dysfunction in rat hearts.

Hornstein PS, Zaugg CE, Zhu P, Allegrini PR, Buser PT.

Br J Pharmacol. 2001 Jan;132(1):234-40.

33.

Transgenic activation of Ras in neurons promotes hypertrophy and protects from lesion-induced degeneration.

Heumann R, Goemans C, Bartsch D, Lingenhöhl K, Waldmeier PC, Hengerer B, Allegrini PR, Schellander K, Wagner EF, Arendt T, Kamdem RH, Obst-Pernberg K, Narz F, Wahle P, Berns H.

J Cell Biol. 2000 Dec 25;151(7):1537-48.

34.

Expression of angiopoietin-1, angiopoietin-2, and tie receptors after middle cerebral artery occlusion in the rat.

Beck H, Acker T, Wiessner C, Allegrini PR, Plate KH.

Am J Pathol. 2000 Nov;157(5):1473-83.

35.

Plasminogen activation in experimental permanent focal cerebral ischemia.

Pfefferkorn T, Wiessner C, Allegrini PR, Staufer B, Vosko MR, Liebetrau M, Bueltemeier G, Kloss CU, Hamann GF.

Brain Res. 2000 Nov 3;882(1-2):19-25.

PMID:
11056180
36.

Protective effect of a caspase inhibitor in models for cerebral ischemia in vitro and in vivo.

Wiessner C, Sauer D, Alaimo D, Allegrini PR.

Cell Mol Biol (Noisy-le-grand). 2000 Feb;46(1):53-62.

PMID:
10726971
37.

Neuron-specific transgene expression of Bcl-XL but not Bcl-2 genes reduced lesion size after permanent middle cerebral artery occlusion in mice.

Wiessner C, Allegrini PR, Rupalla K, Sauer D, Oltersdorf T, McGregor AL, Bischoff S, Böttiger BW, van der Putten H.

Neurosci Lett. 1999 Jun 25;268(3):119-22.

PMID:
10406019
38.

Cell type specific upregulation of vascular endothelial growth factor in an MCA-occlusion model of cerebral infarct.

Plate KH, Beck H, Danner S, Allegrini PR, Wiessner C.

J Neuropathol Exp Neurol. 1999 Jun;58(6):654-66.

PMID:
10374756
39.

Bradykinin-dependent cardioprotective effects of losartan against ischemia and reperfusion in rat hearts.

Zhu P, Zaugg CE, Hornstein PS, Allegrini PR, Buser PT.

J Cardiovasc Pharmacol. 1999 May;33(5):785-90.

PMID:
10226867
40.

Time course of microglia activation and apoptosis in various brain regions after permanent focal cerebral ischemia in mice.

Rupalla K, Allegrini PR, Sauer D, Wiessner C.

Acta Neuropathol. 1998 Aug;96(2):172-8.

PMID:
9705133
41.

Reperfusion after thrombolytic therapy of embolic stroke in the rat: magnetic resonance and biochemical imaging.

Busch E, Krüger K, Allegrini PR, Kerskens CM, Gyngell ML, Hoehn-Berlage M, Hossmann KA.

J Cereb Blood Flow Metab. 1998 Apr;18(4):407-18.

PMID:
9538906
42.

Blood-brain barrier disturbances after rt-PA treatment of thromboembolic stroke in the rat.

Busch E, Krüger K, Fritze K, Allegrini PR, Hoehn-Berlage M, Hossmann KA.

Acta Neurochir Suppl. 1997;70:206-8.

PMID:
9416323
43.

Exploration of P-type Ca2+ channels as drug targets for the treatment of epilepsy or ischemic stroke.

Lingenhöhl K, Small DL, Monette R, Buchan AM, Morley P, Allegrini PR, Fröst LW, Sauer D, Schmutz M, Knöpfel T.

Neuropharmacology. 1997 Jan;36(1):107-13.

PMID:
9144647
44.

Endothelin-1-induced release of thromboxane A2 increases the vasoconstrictor effect of endothelin-1 in postischemic reperfused rat hearts.

Zaugg CE, Hornstein PS, Zhu P, Simper D, Lüscher TF, Allegrini PR, Buser PT.

Circulation. 1996 Aug 15;94(4):742-7.

PMID:
8772697
45.
46.

CGP 53153: a new potent inhibitor of 5alpha-reductase.

Häusler A, Allegrini PR, Biollaz M, Batzl C, Scheidegger E, Bhatnagar AS.

J Steroid Biochem Mol Biol. 1996 Feb;57(3-4):187-95.

PMID:
8645628
47.

The competitive NMDA antagonist CGP 40116 permanently reduces brain damage after middle cerebral artery occlusion in rats.

Sauer D, Weber E, Lüönd G, Da Silva F, Allegrini PR.

J Cereb Blood Flow Metab. 1995 Jul;15(4):602-10.

PMID:
7790408
48.

Bradykinin improves postischaemic recovery in the rat heart: role of high energy phosphates, nitric oxide, and prostacyclin.

Zhu P, Zaugg CE, Simper D, Hornstein P, Allegrini PR, Buser PT.

Cardiovasc Res. 1995 May;29(5):658-63.

PMID:
7606754
49.

Conductance catheter measurement of left ventricular volume: evidence for nonlinearity within cardiac cycle.

Szwarc RS, Laurent D, Allegrini PR, Ball HA.

Am J Physiol. 1995 Apr;268(4 Pt 2):H1490-8.

PMID:
7733350
50.

Supplemental Content

Loading ...
Support Center